Marshall Wace North America L.P. Invests $612,000 in Insys Therapeutics, Inc. (INSY) Stock
Marshall Wace North America L.P. acquired a new position in Insys Therapeutics, Inc. (NASDAQ:INSY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 47,096 shares of the specialty pharmaceutical company’s stock, valued at approximately $612,000. Marshall Wace North America L.P. owned 0.07% of Insys Therapeutics at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. BNP Paribas Arbitrage SA raised its position in Insys Therapeutics by 213.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock worth $166,000 after purchasing an additional 8,940 shares during the period. Bank of New York Mellon Corp raised its position in Insys Therapeutics by 1.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 156,471 shares of the specialty pharmaceutical company’s stock worth $1,980,000 after purchasing an additional 1,876 shares during the period. SG Americas Securities LLC purchased a new stake in Insys Therapeutics in the 2nd quarter worth about $138,000. State of Wisconsin Investment Board purchased a new stake in Insys Therapeutics in the 2nd quarter worth about $240,000. Finally, Rhumbline Advisers raised its position in Insys Therapeutics by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 30,970 shares of the specialty pharmaceutical company’s stock worth $392,000 after purchasing an additional 1,793 shares during the period. 25.45% of the stock is currently owned by institutional investors.
Shares of Insys Therapeutics, Inc. (NASDAQ INSY) opened at 9.61 on Wednesday. The company has a 50-day moving average of $9.87 and a 200-day moving average of $11.28. Insys Therapeutics, Inc. has a 52-week low of $8.70 and a 52-week high of $15.06. The stock’s market capitalization is $698.61 million.
Insys Therapeutics (NASDAQ:INSY) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. The company had revenue of $42.60 million for the quarter, compared to analyst estimates of $36.90 million. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. Insys Therapeutics’s revenue was down 38.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.13 EPS. Equities research analysts anticipate that Insys Therapeutics, Inc. will post ($0.29) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/13/marshall-wace-north-america-l-p-invests-612000-in-insys-therapeutics-inc-insy-stock.html.
A number of analysts recently weighed in on the stock. Royal Bank Of Canada set a $16.00 price objective on shares of Insys Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 3rd. Zacks Investment Research raised shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 price objective on the stock in a research report on Wednesday, July 12th. BidaskClub raised shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $10.00 price objective on shares of Insys Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $13.25.
In related news, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of Insys Therapeutics stock in a transaction dated Friday, August 11th. The shares were acquired at an average cost of $8.93 per share, with a total value of $156,275.00. Following the purchase, the insider now owns 31,982 shares of the company’s stock, valued at $285,599.26. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Saeed Motahari purchased 5,500 shares of Insys Therapeutics stock in a transaction dated Thursday, August 10th. The stock was bought at an average cost of $8.92 per share, for a total transaction of $49,060.00. Following the completion of the purchase, the chief executive officer now directly owns 15,400 shares in the company, valued at approximately $137,368. The disclosure for this purchase can be found here. Insiders own 67.90% of the company’s stock.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.